Search results
Results from the WOW.Com Content Network
Surgical risk, age, perceived life expectancy, and valve durability influence the choice between surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation. The contemporaneous life expectancy after SAVR, in relation to surgical risk and age, is unknown.
Based on the simulation model, the durability of TAVR valves must be 70% shorter than that of surgical valves to result in reduced life expectancy in older low-risk patients. The threshold for TAVR device durability was substantially higher in younger low-risk patients.
From April 2008 to December 2020, a total of 991 patients with symptomatic severe aortic stenosis underwent TAVR with balloon-expandable or self-expanding valves were included. Primary outcomes and survival analysed on base to age <75 years and ≥75 years old.
Transcatheter aortic valve replacement (TAVR) becomes the leading therapeutic choice for severe aortic stenosis. There is a growing body of knowledge on long-term survival outcomes, but available data from real-world observational studies are scarce.
This data suggests that a 42-year-old patient undergoing aortic valve replacement (AVR) with a tissue valve is expected to live to 58 years of age. In contrast, a 42-year-old in the general population is expected to live to 78 years of age.
A transcatheter aortic valve replacement (TAVR) procedure replaces a damaged aortic valve with a new one. TAVR is minimally invasive and may improve quality of life.
Results of the base case examining the impact of the event time ratio (ETR) for transcatheter aortic valve replacement (TAVR) valve durability on life expectancy when patients undergo valve-in-valve TAVR as the initial management strategy for a failed prosthesis.
Contemporary data on loss in life expectancy after aortic valve replacement (AVR) are scarce, particularly in younger patients. The purpose of this national, observational cohort study was to analyze long-term relative survival and estimated loss in life expectancy after AVR.
They found that the loss in life expectancy after SAVR was 0.4 years in patients age 80 years or older. In younger patients however, loss in life expectancy after SAVR was relatively high (4.4 and 3.8 years loss in patients age <50 years and age 50 to 59 years, respectively).
Transcatheter aortic valve replacement (TAVR) has significantly changed the management of symptomatic severe aortic stenosis (AS) over the past 20 years: from the initial indication as a valid alternative to surgery in patients with extreme or high surgical risk, to recent randomized trials data (Table) showing non-inferiority in intermediate an...